This is an old revision of this page, as edited by PotatoBot (talk | contribs) at 17:33, 13 September 2011 (Stub sorting and placement of stub template(s): monoclonal-antibody-, antineoplastic-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 17:33, 13 September 2011 by PotatoBot (talk | contribs) (Stub sorting and placement of stub template(s): monoclonal-antibody-, antineoplastic-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD44 v6 |
| Clinical data | |
| ATC code |
|
| (verify) | |
Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.
References
- Tijink, BM; Buter, J; De Bree, R; Giaccone, G; Lang, MS; Staab, A; Leemans, CR; Van Dongen, GA (2006). "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus". Clinical cancer research : an official journal of the American Association for Cancer Research. 12 (20 Pt 1): 6064–72. doi:10.1158/1078-0432.CCR-06-0910. PMID 17062682.
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |